CCR8

Note

CCR8 타겟 임상시험 모니터링

Visual Summary

Change History

  • 2026-04-01 03:02:47: Changes detected in 1 trials: NCT06657144
  • 2026-03-31 02:51:38: Changes detected in 1 trials: NCT06657144
  • 2026-03-26 02:49:53: Changes detected in 1 trials: NCT07205718
  • 2026-03-21 02:25:16: Changes detected in 3 trials: NCT04895709, NCT07011550, NCT05537740
  • 2026-03-20 02:30:50: Changes detected in 1 trials: NCT05635643
  • 2026-03-19 02:45:05: Changes detected in 1 trials: NCT05101070
  • 2026-03-14 02:07:20: Changes detected in 2 trials: NCT06825494, NCT05935098
  • 2026-03-12 02:11:53: Changes detected in 1 trials: NCT07011550
  • 2026-03-11 02:05:42: Changes detected in 2 trials: NCT06821503, NCT06819735
  • 2026-03-03 00:59:11: Changes detected in 1 trials: NCT06657144

NCT04895709

  • 2026-03-21 02:05:09 (Trial Update)
    • Field `contactsLocationsModule.locations.[39]city` changed from `Napoli` to `Naples`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lat` changed from `40.87618` to `40.85216`
    • Field `contactsLocationsModule.locations.[39]geoPoint.lon` changed from `14.5195` to `14.26811`
  • 2026-02-26 00:55:48 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-12` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-12-16` to `2026-02-23`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-17` to `2026-02-25`
    • Field `contactsLocationsModule.centralContacts.[0]name` changed from `BMS Study Connect Contact Center www.BMSStudyConnect.com` to `BMS Clinical Trials Contact Center www.BMSClinicalTrials.com`
    • Field `contactsLocationsModule.locations.[3]status` changed from `COMPLETED` to `ACTIVE_NOT_RECRUITING`
    • Field `contactsLocationsModule.locations.[7]status` changed from `COMPLETED` to `ACTIVE_NOT_RECRUITING`
    • New field added: `root['ipdSharingStatementModule']`

NCT06825494

  • 2026-03-14 02:07:19 (Trial Update)
    • Field `contactsLocationsModule.locations.[10]geoPoint.lat` changed from `32.99472` to `33.00524`
    • Field `contactsLocationsModule.locations.[10]geoPoint.lon` changed from `112.53278` to `112.54659`

NCT06821503

  • 2026-03-11 02:05:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2024-12` to `2025-12`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `statusModule.startDateStruct.date` changed from `2025-02` to `2025-04-11`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-02-13` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-02-17` to `2026-03-10`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Inclusion Criteria:
      • Age 18 or above.
      • The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.
      • There should be at least one measurable lesion.
      • All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion/exclusion criteria.
      • Have sufficient organ and bone marrow function
      • Expected survival period ≥ 12 weeks
      • Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.
      • With my consent and signed informed consent form.
      • Patients diagnosed with Pancreatic ductal adenocarcinoma (PDAC) by pathology have evidence of advanced stage or metastasis that cannot be surgically removed.
      • Have not received systematic treatment for unresectable locally advanced or metastatic PDAC in the past
    • Exclusion Criteria:
      • Known High-frequency microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
      • There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and/or progressive growth.
      • Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.
      • Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.
      • Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg/m ² within the first 2 months of enrollment.
      • Received the following treatments or medications before enrollment:
      1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.
      1. Having undergone major surgery within 28 days prior to enrollment.
      1. Used immunosuppressive drugs within 14 days prior to enrollment.
      1. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.
      1. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.
      • Diagnosed with any other malignant tumor within the 5 years prior to enrollment.
      • There are any active, known or suspected autoimmune diseases present.
      • Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial/venous thrombotic events that occurred within the first 6 months of enrollment.
      • Significant vascular disease occurred within the first 6 months of enrollment.
      • Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.
      • There is peripheral neuropathy of grade>1 present.
      • Have experienced gastrointestinal perforation and/or gastrointestinal fistula within the 6 months prior to enrollment;
      • Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction.
      • Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.
      • Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.
      • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.
      • Clinical symptoms or diseases of the heart that have not been well controlled:
      • Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever>38.5 °C during screening/before first administration.
      • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
      • Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.
      • Known history of abuse or drug use of psychotropic substances.
      • There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.` to `Inclusion Criteria:
      • Age 18 or above.
      • The Eastern Cooperative Oncology Group (ECOG) physical fitness status score is 0-1 points.
      • There should be at least one measurable lesion.
      • All acute toxic reactions caused by previous anti-tumor treatments or surgical procedures have been relieved to grade 0-1 or to the levels specified in the inclusion/exclusion criteria.
      • Have sufficient organ and bone marrow function
      • Expected survival period ≥ 12 weeks
      • Infertility is defined as women who have reached menopause or have undergone bilateral oophorectomy with medical records. Male participants and female participants with fertility must agree to use one medically approved contraceptive measure during the trial period and within 6 months after the last administration of the trial drug or within 9 months after the last administration of chemotherapy drug (oxaliplatin) (whichever is later). The serum pregnancy test must be negative within 3 days before starting the study medication and not during lactation.
      • With my consent and signed informed consent form.
      • Patients with a pathological diagnosis of pancreatic cancer (ductal adenocarcinoma or adenocarcinoma) have evidence of advanced or metastatic disease that is not resectable.
      • Previously received no systemic treatment for unresectable locally advanced or metastatic pancreatic cancer.
    • Exclusion Criteria:
      • Known High-frequency microsatellite instability (MSI-H)/deficient mismatch repair (dMMR).
      • There is uncontrolled or symptomatic active central nervous system metastasis, which can manifest as clinical symptoms, cerebral edema, spinal cord compression, cancerous meningitis, leptomeningeal disease, and/or progressive growth.
      • Within 14 days prior to enrollment, there were still uncontrollable pleural effusion and ascites despite treatment such as puncture and drainage; Pericardial effusion accompanied by clinical symptoms or moderate or above.
      • Within 14 days prior to enrollment, there is an unresolved biliary obstruction, or the clinical status has remained stable for less than 14 days after biliary stent implantation.
      • Participants' weight has decreased by more than 20% or their body mass index (BMI) is less than 18 kg/m ² within the first 2 months of enrollment.
      • Received the following treatments or medications before enrollment:
      1. Prior to enrollment, received treatment with C-C chemokine Receptor 8 (CCR8) antibodies, cytotoxic T-lymphocyte associated protein-4 (CTLA-4) antibodies, or other drugs that act on Tregs.
      1. Having undergone major surgery within 28 days prior to enrollment.
      1. Used immunosuppressive drugs within 14 days prior to enrollment.
      1. Vaccination with attenuated live vaccine should be administered within 28 days prior to enrollment or planned within the study period and 60 days after completion of study drug treatment.
      1. Received anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, endocrine therapy, targeted therapy, biological therapy, or tumor embolization) within 28 days before enrollment.
      • Diagnosed with any other malignant tumor within the 5 years prior to enrollment.
      • There are any active, known or suspected autoimmune diseases present.
      • Within the first 3 months of enrollment, there have been significant clinical bleeding symptoms or clear bleeding tendencies; Arterial/venous thrombotic events that occurred within the first 6 months of enrollment.
      • Significant vascular disease occurred within the first 6 months of enrollment.
      • Severe, unhealed, or cracked wounds, as well as active ulcers or untreated fractures.
      • There is peripheral neuropathy of grade>1 present.
      • Have experienced gastrointestinal perforation and/or gastrointestinal fistula within the 6 months prior to enrollment;
      • Within the 6 months prior to enrollment, there have been clinical signs or symptoms of intestinal obstruction and/or gastrointestinal obstruction.
      • Existence of interstitial lung disease, non infectious pneumonia, or uncontrolled systemic diseases.
      • Known to be allergic to the investigational drug or any of its excipients; Or have experienced severe allergic reactions to other monoclonal antibodies.
      • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), untreated active hepatitis or co infection with hepatitis B and hepatitis C.
      • Clinical symptoms or diseases of the heart that have not been well controlled:
      • Systemic use of antibiotics for at least 7 days within the 28 days prior to enrollment, or unexplained fever>38.5 °C during screening/before first administration.
      • Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
      • Have participated in any other drug clinical studies within 4 weeks prior to enrollment, or have not had more than 5 half lives since the last study medication.
      • Known history of abuse or drug use of psychotropic substances.
      • There are other serious physical or mental illnesses or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the study results, as well as patients who the researcher deems unsuitable to participate in this study.`
    • Field `contactsLocationsModule.locations.[15]` changed from `{'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Jihui Hao, Doctor', 'role': 'CONTACT', 'phone': '18622221120', 'email': 'haojihui@tjmuch.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}` to `{'facility': 'Tianjin Medical University Cancer Institute & Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Jihui Hao, Doctor', 'role': 'CONTACT', 'phone': '18622221120', 'email': 'haojihui@tjmuch.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}`
    • Field `contactsLocationsModule.locations.[3]` changed from `{'facility': 'Chongqing Qeneral Hospital', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'zip': '400013', 'country': 'China', 'contacts': [{'name': 'Huaizhi Wang, Doctor', 'role': 'CONTACT', 'phone': '13996950719', 'email': 'whuaizhi@qq.com'}], 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}` to `{'facility': 'Chongqing Qeneral Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'zip': '400013', 'country': 'China', 'contacts': [{'name': 'Huaizhi Wang, Doctor', 'role': 'CONTACT', 'phone': '13996950719', 'email': 'whuaizhi@qq.com'}], 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}`
    • Field `contactsLocationsModule.locations.[6]` changed from `{'facility': 'Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430000', 'country': 'China', 'contacts': [{'name': 'Jun Xue, Doctor', 'role': 'CONTACT', 'phone': '15071258754', 'email': 'xjunion@126.com'}], 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}` to `{'facility': 'Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology', 'status': 'NOT_YET_RECRUITING', 'city': 'Wuhan', 'state': 'Hubei', 'zip': '430000', 'country': 'China', 'contacts': [{'name': 'Jun Xue, Doctor', 'role': 'CONTACT', 'phone': '15071258754', 'email': 'xjunion@126.com'}], 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}`
    • Field `contactsLocationsModule.locations.[8]` changed from `{'facility': "Jiangsu Provincial People's Hospital", 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Kuirong Jiang, Doctor', 'role': 'CONTACT', 'phone': '15312995688', 'email': 'jiangkuirong@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}` to `{'facility': "Jiangsu Provincial People's Hospital", 'status': 'NOT_YET_RECRUITING', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Kuirong Jiang, Doctor', 'role': 'CONTACT', 'phone': '15312995688', 'email': 'jiangkuirong@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}`
    • Field `contactsLocationsModule.locations.[2]` changed from `{'facility': 'Beijing Cancer Hospital', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100142', 'country': 'China', 'contacts': [{'name': 'Lin Shen, Doctor', 'role': 'CONTACT', 'phone': '010-88196561', 'email': 'doctorshenlin@sina.cn'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Beijing Cancer Hospital', 'status': 'RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100142', 'country': 'China', 'contacts': [{'name': 'Lin Shen, Doctor', 'role': 'CONTACT', 'phone': '010-88196561', 'email': 'doctorshenlin@sina.cn'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`
    • Field `contactsLocationsModule.locations.[4]` changed from `{'facility': 'Harbin Medical University Cancer Hospital', 'city': 'Harbin', 'state': 'Heilongjiang', 'zip': '150081', 'country': 'China', 'contacts': [{'name': 'Zhiwei Li, Doctor', 'role': 'CONTACT', 'phone': '15004683651', 'email': 'lzhw0451@163.com'}], 'geoPoint': {'lat': 45.75, 'lon': 126.65}}` to `{'facility': 'Harbin Medical University Cancer Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Harbin', 'state': 'Heilongjiang', 'zip': '150081', 'country': 'China', 'contacts': [{'name': 'Zhiwei Li, Doctor', 'role': 'CONTACT', 'phone': '15004683651', 'email': 'lzhw0451@163.com'}], 'geoPoint': {'lat': 45.75, 'lon': 126.65}}`
    • Field `contactsLocationsModule.locations.[12]` changed from `{'facility': "The First Affiliated Hospital of Xi'an Jiaotong University Medical College", 'city': "Xi'an", 'state': 'Shaanxi', 'zip': '710000', 'country': 'China', 'contacts': [{'name': 'Zheng Wu, Doctor', 'role': 'CONTACT', 'phone': '13609195898', 'email': 'woozheng@xjtu.edu.cn'}], 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}` to `{'facility': "The First Affiliated Hospital of Xi'an Jiaotong University Medical College", 'status': 'NOT_YET_RECRUITING', 'city': "Xi'an", 'state': 'Shaanxi', 'zip': '710000', 'country': 'China', 'contacts': [{'name': 'Zheng Wu, Doctor', 'role': 'CONTACT', 'phone': '13609195898', 'email': 'woozheng@xjtu.edu.cn'}], 'geoPoint': {'lat': 34.25833, 'lon': 108.92861}}`
    • Field `contactsLocationsModule.locations.[14]` changed from `{'facility': 'Tianjin Cancer Hospital Airport Hospital', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Huikai Li, Doctor', 'role': 'CONTACT', 'phone': '18622228639', 'email': 'tjchlhk@126.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}` to `{'facility': 'Tianjin Cancer Hospital Airport Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Tianjin', 'state': 'Tianjin Municipality', 'zip': '300000', 'country': 'China', 'contacts': [{'name': 'Huikai Li, Doctor', 'role': 'CONTACT', 'phone': '18622228639', 'email': 'tjchlhk@126.com'}], 'geoPoint': {'lat': 39.14222, 'lon': 117.17667}}`
    • Field `contactsLocationsModule.locations.[13]` changed from `{'facility': 'The First Affiliated Hospital of Naval Medical University', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'zip': '200336', 'country': 'China', 'contacts': [{'name': 'Gang Jin, Doctor', 'role': 'CONTACT', 'phone': '13601635681', 'email': 'Jigang@sohu.com'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}` to `{'facility': 'The First Affiliated Hospital of Naval Medical University', 'status': 'NOT_YET_RECRUITING', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'zip': '200336', 'country': 'China', 'contacts': [{'name': 'Gang Jin, Doctor', 'role': 'CONTACT', 'phone': '13601635681', 'email': 'Jigang@sohu.com'}], 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}`
    • Field `contactsLocationsModule.locations.[9]` changed from `{'facility': 'The First Affiliated Hospital of Nanchang University', 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '330006', 'country': 'China', 'contacts': [{'name': 'Yong Li, Doctor', 'role': 'CONTACT', 'phone': '15879155066', 'email': 'liyong1553@163.com'}], 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}` to `{'facility': 'The First Affiliated Hospital of Nanchang University', 'status': 'NOT_YET_RECRUITING', 'city': 'Nanchang', 'state': 'Jiangxi', 'zip': '330006', 'country': 'China', 'contacts': [{'name': 'Yong Li, Doctor', 'role': 'CONTACT', 'phone': '15879155066', 'email': 'liyong1553@163.com'}], 'geoPoint': {'lat': 28.68396, 'lon': 115.85306}}`
    • Field `contactsLocationsModule.locations.[5]` changed from `{'facility': 'The First Affiliated Hospital of Zhengzhou University', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450000', 'country': 'China', 'contacts': [{'name': 'Feng Wang, Doctor', 'role': 'CONTACT', 'phone': '13938244776', 'email': 'fengw010@163.com'}, {'name': 'Aili Suo Suo, Doctor', 'role': 'CONTACT', 'phone': '18991232561', 'email': 'Ailisuo@mail.xjtu.edu.cn'}], 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}` to `{'facility': 'The First Affiliated Hospital of Zhengzhou University', 'status': 'NOT_YET_RECRUITING', 'city': 'Zhengzhou', 'state': 'Henan', 'zip': '450000', 'country': 'China', 'contacts': [{'name': 'Feng Wang, Doctor', 'role': 'CONTACT', 'phone': '13938244776', 'email': 'fengw010@163.com'}, {'name': 'Aili Suo Suo, Doctor', 'role': 'CONTACT', 'phone': '18991232561', 'email': 'Ailisuo@mail.xjtu.edu.cn'}], 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}`
    • Field `contactsLocationsModule.locations.[7]` changed from `{'facility': 'Jiangsu Cancer Hospital', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Xiaofeng Sun, Master', 'role': 'CONTACT', 'phone': '13505156959', 'email': 'jssxfgcp@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}` to `{'facility': 'Jiangsu Cancer Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Nanjing', 'state': 'Jiangsu', 'zip': '210000', 'country': 'China', 'contacts': [{'name': 'Xiaofeng Sun, Master', 'role': 'CONTACT', 'phone': '13505156959', 'email': 'jssxfgcp@163.com'}], 'geoPoint': {'lat': 32.06167, 'lon': 118.77778}}`
    • Field `contactsLocationsModule.locations.[10]` changed from `{'facility': 'The First Affiliated Hospital of China Medical University', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110000', 'country': 'China', 'contacts': [{'name': 'Xiujuan Qu, Doctor', 'role': 'CONTACT', 'phone': '13604031355', 'email': 'qu_xiujuan@hotmail.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}` to `{'facility': 'The First Affiliated Hospital of China Medical University', 'status': 'NOT_YET_RECRUITING', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110000', 'country': 'China', 'contacts': [{'name': 'Xiujuan Qu, Doctor', 'role': 'CONTACT', 'phone': '13604031355', 'email': 'qu_xiujuan@hotmail.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}`
    • Field `contactsLocationsModule.locations.[1]` changed from `{'facility': 'Cancer Hospital Chinese Academy of Medical Science', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100021', 'country': 'China', 'contacts': [{'name': 'Yongkun Sun, Doctor', 'role': 'CONTACT', 'phone': '13141276041', 'email': 'hsunyk@126.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Cancer Hospital Chinese Academy of Medical Science', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100021', 'country': 'China', 'contacts': [{'name': 'Yongkun Sun, Doctor', 'role': 'CONTACT', 'phone': '13141276041', 'email': 'hsunyk@126.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`
    • Field `contactsLocationsModule.locations.[11]` changed from `{'facility': "The Sixth People's Hospital of Shenyang", 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110002', 'country': 'China', 'contacts': [{'name': 'Jin Xu, Doctor', 'role': 'CONTACT', 'phone': '13236666950', 'email': 'xvjin2024@sina.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}` to `{'facility': "The Sixth People's Hospital of Shenyang", 'status': 'NOT_YET_RECRUITING', 'city': 'Shenyang', 'state': 'Liaoning', 'zip': '110002', 'country': 'China', 'contacts': [{'name': 'Jin Xu, Doctor', 'role': 'CONTACT', 'phone': '13236666950', 'email': 'xvjin2024@sina.com'}], 'geoPoint': {'lat': 41.79222, 'lon': 123.43278}}`
    • Field `contactsLocationsModule.locations.[0]` changed from `{'facility': 'Peking Union Medical College Hospital', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100005', 'country': 'China', 'contacts': [{'name': 'Xicheng Wang, Doctor', 'role': 'CONTACT', 'phone': '13439563949', 'email': 'xicheng_wang@hotmail.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}` to `{'facility': 'Peking Union Medical College Hospital', 'status': 'NOT_YET_RECRUITING', 'city': 'Beijing', 'state': 'Beijing Municipality', 'zip': '100005', 'country': 'China', 'contacts': [{'name': 'Xicheng Wang, Doctor', 'role': 'CONTACT', 'phone': '13439563949', 'email': 'xicheng_wang@hotmail.com'}], 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}`

NCT05581004

  • 2026-02-18 01:00:46 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-16` to `2026-02-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-20` to `2026-02-17`
    • Field `contactsLocationsModule.locations.[22]city` changed from `N. Efkapria-Pavlos Melas` to `Pavlos Melas`
    • Field `contactsLocationsModule.locations.[30]facility` changed from `ICO l?Hospitalet ? Hospital Duran i Reynals` to `ICO Hospitalet- Hospital Duran i Reynals`

NCT06819735

  • 2026-03-11 02:05:41 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-14` to `2026-03-06`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-11-18` to `2026-03-10`

NCT06911827

  • 2026-02-26 00:55:48 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-03` to `2026-02`
    • Field `statusModule.overallStatus` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `statusModule.startDateStruct.date` changed from `2025-04` to `2025-05-09`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-04-07` to `2026-02-24`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-04-09` to `2026-02-25`
    • New field added: `root['contactsLocationsModule']['locations']`

NCT07011550

  • 2026-03-21 02:05:09 (Trial Update)
    • Field `statusModule.whyStopped` changed from `FDA` to `PI Request`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-10` to `2026-03-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-11` to `2026-03-20`
  • 2026-03-12 02:11:52 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-10`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-24` to `2026-03-11`
  • 2026-02-25 01:02:23 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-17` to `2026-02-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-19` to `2026-02-24`
    • Field removed: `root['statusModule']['expandedAccessInfo']`
  • 2026-02-20 00:56:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-08` to `2026-02`
    • Field `statusModule.overallStatus` changed from `RECRUITING` to `SUSPENDED`
    • Field `statusModule.startDateStruct.date` changed from `2025-11-30` to `2025-08-15`
    • Field `statusModule.startDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-08-20` to `2026-02-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-27` to `2026-02-19`
    • Field `designModule.enrollmentInfo.count` changed from `40` to `7`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`
    • Field removed: `root['contactsLocationsModule']['centralContacts']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['status']`
    • Field removed: `root['contactsLocationsModule']['locations'][0]['contacts']`

NCT05101070

  • 2026-03-19 02:24:59 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-04` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-04-16` to `2028-05-31`
    • Field `statusModule.completionDateStruct.date` changed from `2027-04-16` to `2028-05-31`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-05-22` to `2026-03-16`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-05-28` to `2026-03-18`
    • Field `descriptionModule.briefSummary` changed from `The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011.
    • The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.` to `The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011 with or without pembrolizumab.
    • The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D with or without pembrolizumab.
    • The primary objective of Parts D and E is to evaluate the antitumor activity of S-531011 at the RP2D in combination with bevacizumab with our without pembrolizumab.`
    • Field `designModule.enrollmentInfo.count` changed from `274` to `282`
    • Field `outcomesModule.secondaryOutcomes.[0]timeFrame` changed from `Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part A-1]; Approximately 24 months [Part A-2])` to `Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part A-1]; Approximately 24 months [Part A-2])`
    • Field `outcomesModule.secondaryOutcomes.[5]measure` changed from `Serum concentrations of S-531011` to `Parts B, C, D, E: Number of Participants with Treatment-emergent Adverse Events (TEAEs)`
    • Field `outcomesModule.secondaryOutcomes.[5]timeFrame` changed from `Part A: Cycle 1, Days 8 and 15 (4 hours post infusion); Cycles 2-9, Day 1 (pre- and end-of-infusion); Safety Follow-up Visit. Parts B and C: Day 1 of Cycles 1-9 (pre- and end-of-infusion); Safety Follow-up Visit. (each cycle is 21 days)` to `Approximately 12 months (Part B); Approximately 24 months (Parts C, D, E)`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Key Inclusion Criteria:
      1. Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements), at the time of signing the informed consent.
      1. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
      1. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1.
      1. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, or triple-negative breast cancer, esophageal cancer (esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (gastric and gastroesophageal junction adenocarcinoma). Participants with colorectal cancer (CRC), pancreatic cancer, cervical cancer, epithelial ovarian cancer, and other types of solid tumors may also be enrolled upon discussion with and approval by the sponsor. For the backfill cohorts only, specific tumor types may be selected.
      1. (Part B CRC cohorts only) Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-epidermal growth factor receptor (EGFR) therapy if rat sarcoma virus (RAS) (Kirsten RAS/neuroblastoma RAS [KRAS/NRAS]) wild-type; V-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Part C CRC cohorts only) Participants must have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type; BRAF inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded tumor tissues (as block or unstained slides) for this study.
      1. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
      1. (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism (flow cytometry) analysis.
      1. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      1. An estimated life expectancy of at least 12 weeks.
      1. Adequate hematologic and organ function as confirmed by laboratory values.
      1. QT interval corrected with the Fridericia formula ≤ 480 milliseconds in 12-lead electrocardiogram at Screening.
    • Key Exclusion Criteria:
      1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 milligrams of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
      1. Presence or history of interstitial lung disease and (non-infectious) pneumonitis that required corticosteroids.
      1. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before the first dose of study intervention.
      1. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association classification III or IV.
      1. A positive test for hepatitis B surface antigen and/or hepatitis C virus (HCV) antibody (participants with positive HCV antibody are eligible if a confirmatory HCV RNA test is undetectable).
      1. A positive serological test for human immunodeficiency virus infection.
      1. Known history of any other relevant congenital or acquired immunodeficiency.
      1. Known history of an allogeneic tissue and/or solid organ transplant.
      1. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
      1. Women who are pregnant or breastfeeding (or have discontinued breastfeeding) or trying to become pregnant.
      1. Clinical evidence of uncontrolled brain metastasis.
      1. Clinically uncontrollable symptomatic pleural effusion and/or ascites. (Participants who do not require fluid drainage or have no significant increase of fluid for 28 days may be eligible with approval by the sponsor.)
      1. Known additional malignancy that is progressing or has required active treatment within the past 3 years.
      1. (Part B and C CRC cohorts only): Colorectal cancer with mismatch repair deficient/microsatellite instability-high status.
      1. (Parts A-2 and C only): Has received prior therapy with an anti-programmed death 1, anti-programmed death ligand 1, or anti-programmed death ligand 2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4, OX-40, CD137), and was discontinued from that treatment due to ≥ Grade 3 immune-related adverse event.
      1. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
      1. Prior major surgery within 28 days before the first dose of study intervention.
      1. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation) or history of radiation pneumonitis.
      1. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
      1. Prior treatment with anti-CCR8 antibody for any indication.
      1. Receipt of hematopoietic growth factors (for example, granulocyte-colony stimulating factor or erythropoietin) within 14 days before the first dose of study intervention or blood transfusions within 14 days before the first dose of study intervention.
      1. Receipt of a live, attenuated vaccine within 30 days before the first dose of study intervention.
    • Note: Additional inclusion/exclusion criteria may apply, per protocol.` to `Eligibility Criteria: Key Inclusion Criteria:
      1. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
      1. Measurable disease by Response Evaluation Criteria in Solid Tumors version 1.1.
      1. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma, head and neck squamous cell carcinoma, renal cell carcinoma, urothelial carcinoma, non-small cell lung cancer, or triple-negative breast cancer, esophageal cancer (esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (gastric and gastroesophageal junction adenocarcinoma). Participants with colorectal cancer (CRC), pancreatic cancer, cervical cancer, epithelial ovarian cancer, and other types of solid tumors may also be enrolled upon discussion with and approval by the sponsor. For the backfill cohorts only, specific tumor types may be selected.
      1. (Part B CRC cohorts only) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-epidermal growth factor receptor (EGFR) therapy if rat sarcoma virus (RAS) (Kirsten RAS/neuroblastoma RAS [KRAS/NRAS]) wild-type and medically appropriate ; V-raf murine sarcoma viral oncogene homolog B (BRAF) inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Part C CRC cohorts only) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type and medically appropriate ; BRAF inhibitor if BRAF V600E mutation. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. (Parts D and E) Participants must have histologically or cytologically confirmed metastatic adenocarcinoma of the colon or rectum, who had disease progression on or after receiving all of the following standard of care systemic therapies for advanced or metastatic disease or who were intolerant to: fluoropyrimidine, oxaliplatin, and irinotecan; anti-EGFR therapy if RAS (KRAS/NRAS) wild-type and medically appropriate; BRAF inhibitor if BRAF-V600E mutation.. In addition, participants who received up to 2 additional lines of therapy for advanced or metastatic disease of the following therapies are also eligible: trifluridine/tipiracil, regorafenib, fruquintinib, other drugs approved in the country, or investigational drugs.
      1. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded tumor tissues (as block or unstained slides) for this study.
      1. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
      1. (Part A and B/CRC Cohorts only; At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism (flow cytometry) analysis.
      1. Eastern Cooperative Oncology Group Performance Status of 0 or 1.
      1. An estimated life expectancy of at least 12 weeks.
      1. Adequate hematologic and organ function as confirmed by laboratory values.
      1. QT interval corrected with the Fridericia formula ≤ 480 milliseconds in 12- lead electrocardiogram at Screening.
    • Key Exclusion Criteria:
      1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 milligrams of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
      1. Presence or history of interstitial lung disease and (non-infectious) pneumonitis that required corticosteroids.
      1. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before the first dose of study intervention.
      1. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association classification III or IV.
      1. A positive test for hepatitis B surface antigen and/or hepatitis C virus (HCV) antibody (participants with positive HCV antibody are eligible if a confirmatory HCV RNA test is undetectable).
      1. A positive serological test for human immunodeficiency virus infection.
      1. Known history of any other relevant congenital or acquired immunodeficiency.
      1. Known history of an allogeneic tissue and/or solid organ transplant.
      1. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
      1. Women who are pregnant or breastfeeding (or have discontinued breastfeeding) or trying to become pregnant.
      1. (Parts D and E only) Serious non-healing wound, non-healing ulcer, or non healing bone fracture.
      1. (Parts D and E only) Presence or history of severe arterial thromboembolic events (for example, cerebral infarction, transient ischemic attacks, myocardial infarction, and angina) within 6 months prior to the first dose of study intervention, and/or ≥ Grade 3 venous thromboembolic events (for example, deep vein thrombosis) within 3 months prior to the first dose of study intervention. Participants who receive a full-dose therapeutic anticoagulation should be excluded.
      1. (Parts D and E only) Known coagulopathy that increases risk of bleeding, bleeding diatheses, or any other hemorrhage/bleeding event of ≥ Grade 3 within 4 weeks prior to the first dose of study intervention.
      1. (Parts D and E only) Presence or history of any life-threatening vascular endothelial growth factor (VEGF)-related adverse event (AE).
      1. (Parts D and E only) Proteinuria ≥ 2+ by urine dipstick test within 4 weeks prior to the first dose of study intervention.
      1. Clinical evidence of uncontrolled brain metastasis.
      1. Clinically uncontrollable symptomatic pleural effusion and/or ascites. (Participants who do not require fluid drainage or have no significant increase of fluid for 28 days may be eligible with approval by the sponsor.)
      1. Known additional malignancy that is progressing or has required active treatment within the past 3 years.
      1. (Part B, C, D and E CRC cohorts only): Colorectal cancer with mismatch repair deficient/microsatellite instability-high status.
      1. (Parts A-2, C and E only): Has received prior therapy with an anti-programmed death 1, anti-programmed death ligand 1, or anti-programmed death ligand 2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (for example, cytotoxic T-lymphocyte-associated protein 4, OX-40, CD137), and was discontinued from that treatment due to ≥ Grade 3 immune-related adverse event.
      1. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
      1. Prior major surgery within 28 days before the first dose of study intervention.
      1. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation) or history of radiation pneumonitis.
      1. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
      1. Prior treatment with anti-CCR8 antibody for any indication.
      1. Receipt of hematopoietic growth factors (for example, granulocyte-colony stimulating factor or erythropoietin) within 14 days before the first dose of study intervention or blood transfusions within 14 days before the first dose of study intervention.
      1. (Parts D and E only) Presence or history of allergic reactions or hypersensitivity to bevacizumab or any of its excipients.
      1. (Parts D and E only) Presence or history of hypersensitivity to Chinese Hamster Ovary cell products or other recombinant human or humanized antibodies.
      1. Receipt of a live, attenuated vaccine within 30 days before the first dose of study intervention.
    • Note: Additional protocol defined Inclusion/Exclusion criteria may apply.`
    • Field `contactsLocationsModule.locations.[0]status` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `contactsLocationsModule.locations.[2]status` changed from `RECRUITING` to `ACTIVE_NOT_RECRUITING`
    • Field `armsInterventionsModule.interventions.[0]` changed from `{'type': 'DRUG', 'name': 'S-531011', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-1: S-531011 Monotherapy', 'Part A-2: S-531011 + Pembrolizumab', 'Part B: S-531011 Monotherapy', 'Part C: S-531011 + Pembrolizumab']}` to `{'type': 'DRUG', 'name': 'S-531011', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-1: S-531011 Monotherapy', 'Part A-2: S-531011 + Pembrolizumab', 'Part B: S-531011 Monotherapy', 'Part C: S-531011 + Pembrolizumab', 'Part D: S-531011 + Bevacizumab', 'Part E: S-531011 + Bevacizumab + Pembrolizumab']}`
    • Field `outcomesModule.primaryOutcomes.[1]` changed from `{'measure': 'Parts B and C: Objective Response Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Objective Response Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[5]` changed from `{'measure': 'Parts B and C: Progression-free Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Progression-free Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `armsInterventionsModule.interventions.[1]` changed from `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-2: S-531011 + Pembrolizumab', 'Part C: S-531011 + Pembrolizumab'], 'otherNames': ['KEYTRUDA']}` to `{'type': 'DRUG', 'name': 'Pembrolizumab', 'description': 'Administered by intravenous infusion', 'armGroupLabels': ['Part A-2: S-531011 + Pembrolizumab', 'Part C: S-531011 + Pembrolizumab', 'Part E: S-531011 + Bevacizumab + Pembrolizumab'], 'otherNames': ['KEYTRUDA']}`
    • Field `outcomesModule.primaryOutcomes.[6]` changed from `{'measure': 'Parts B and C: Overall Survival', 'timeFrame': 'From first dose to death, or up to a maximum of 18 months after last dose in the last participant'}` to `{'measure': 'Parts B, C, D, E: Overall Survival', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[2]` changed from `{'measure': 'Parts B and C: Duration of Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Duration of Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[3]` changed from `{'measure': 'Parts B and C: Disease Control Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Disease Control Rate', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`
    • Field `outcomesModule.primaryOutcomes.[4]` changed from `{'measure': 'Parts B and C: Time to Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Part C])'}` to `{'measure': 'Parts B, C, D, E: Time to Response', 'timeFrame': 'Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until disease progression (Approximately 12 months [Part B]; Approximately 24 months [Parts C, D, E])'}`

NCT05537740

  • 2026-03-21 02:05:09 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-07-07` to `2027-04-30`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-20` to `2026-03-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-23` to `2026-03-20`
    • Field `contactsLocationsModule.locations.[20]facility` changed from `Clinica Universidad de Navarra | Pamplona | Oncologia` to `Clinica Universidad De Navarra | Pamplona | Oncologia`
    • Field `contactsLocationsModule.locations.[22]facility` changed from `Clinica Universidad de Navarra | Madrid | Oncologia` to `Clinica Universidad De Navarra | Madrid | Oncologia`
    • New field added: `root['contactsLocationsModule']['locations'][14]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][13]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][15]['state']`
    • New field added: `root['contactsLocationsModule']['locations'][16]['state']`
  • 2026-02-24 00:57:04 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-21` to `2026-02-20`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-22` to `2026-02-23`
    • Field `contactsLocationsModule.locations.[20]facility` changed from `Clinica Universidad De Navarra | Oncologia Medica` to `Clinica Universidad de Navarra | Pamplona | Oncologia`
    • Field `contactsLocationsModule.locations.[22]facility` changed from `Clinica Universidad De Navarra | Oncologia Medica` to `Clinica Universidad de Navarra | Madrid | Oncologia`
  • 2026-02-12 14:01:36 (Trial Update)
    • Field removed: `root['referencesModule']['seeAlsoLinks']`

NCT07205718

  • 2026-03-26 02:29:47 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-04` to `2026-03-24`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-06` to `2026-03-25`
    • Field `contactsLocationsModule.locations.[7]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[9]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
  • 2026-02-10 07:03:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-11` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-11-28` to `2026-02-04`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-12-01` to `2026-02-06`
    • Field `contactsLocationsModule.locations.[2]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[4]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`
    • Field `contactsLocationsModule.locations.[10]status` changed from `NOT_YET_RECRUITING` to `RECRUITING`

NCT05635643

  • 2026-03-20 02:10:44 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2025-07` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2026-02` to `2026-09-30`
    • Field `statusModule.completionDateStruct.date` changed from `2026-02` to `2027-01-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-07-30` to `2026-03-17`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-08-01` to `2026-03-19`

NCT05935098

  • 2026-03-14 02:07:20 (Trial Update)
    • Field `identificationModule.organization.fullName` changed from `BeiGene` to `BeOne Medicines`
    • Field `statusModule.statusVerifiedDate` changed from `2025-06` to `2026-03`
    • Field `statusModule.overallStatus` changed from `ACTIVE_NOT_RECRUITING` to `TERMINATED`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-03-31` to `2026-01-27`
    • Field `statusModule.primaryCompletionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.completionDateStruct.date` changed from `2027-03-31` to `2026-01-27`
    • Field `statusModule.completionDateStruct.type` changed from `ESTIMATED` to `ACTUAL`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2025-06-23` to `2026-03-11`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2025-06-25` to `2026-03-13`
    • Field `designModule.enrollmentInfo.count` changed from `263` to `99`
    • Field `designModule.enrollmentInfo.type` changed from `ESTIMATED` to `ACTUAL`
    • New field added: `root['statusModule']['whyStopped']`

NCT06657144

  • 2026-04-01 02:42:41 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-03-25` to `2026-03-27`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-30` to `2026-03-31`
  • 2026-03-31 02:31:36 (Trial Update)
    • Field `identificationModule.briefTitle` changed from `A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors` to `A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors`
    • Field `identificationModule.officialTitle` changed from `A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors` to `A Phase 1B, Multicenter, Open-Label Study of the Safety and Efficacy of CHS-114 in Combination With Toripalimab With or Without Other Treatments in Participants With Advanced or Metastatic Solid Tumors (TREGCHECK 102)`
    • Field `statusModule.statusVerifiedDate` changed from `2026-02` to `2026-03`
    • Field `statusModule.primaryCompletionDateStruct.date` changed from `2027-05` to `2028-01`
    • Field `statusModule.completionDateStruct.date` changed from `2027-05` to `2028-01`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-26` to `2026-03-25`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-03-02` to `2026-03-30`
    • Field `eligibilityModule.eligibilityCriteria` changed from `Key Inclusion Criteria:
      • At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator.
      • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgement.
    • Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma that is human epidermal growth factor receptor 2 (HER2) - negative and microsatellite stable (MSS)/proficient mismatch repair (pMMR).
      • Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet with or without anti-programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1)-directed therapy (that is, in the second line setting).
      • Consent to provide tumor tissue samples (baseline and on-treatment) is required for enrollment.
    • Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
      • Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel with or without anti-PD-1/PD-L1-directed therapy or anti-CTLA-4 and anti-PD-1/PD-L1-directed combination therapy.
      • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
      • Consent to provide archival tumor tissue sample (baseline) is required for enrolment.
    • Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
      • Consent to provide baseline tumor tissue is required.
      • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
      • Calculated creatinine clearance ≥60 mL/min.
    • Cohort D (4L+ Colorectal Carcinoma [CRC]) - Specific Inclusion Criteria:
      • Histologically and/or cytologically documented unresectable advanced or metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability/mismatch repair status for each participant must be documented, according to country level guidelines.
      • Participants who have no approved standard therapies with a proven clinical benefit available in the participant's country. These therapies include fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, anti-VEGF biological therapy (eg, bevacizumab, aflibercept, ramucirumab), an anti-EGFR therapy (eg, cetuximab, panitumumab) if RAS wildtype unless right-sided, trifluridine/tipiracil or regorafenib, and a BRAF inhibitor (ie, encorafenib) in BRAF V600E mutant).
      • Participants who received oxaliplatin in the adjuvant setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxalipatin-based therapy in the metastatic setting.
      • Consent to provide baseline tumor tissue sample is required for enrolment.
    • Key Exclusion Criteria:
      • History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
      • Symptomatic or untreated central nervous system metastases, including leptomeningeal metastases, requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids.
      • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
      • Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody.
      • History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody (mAb) therapy or any excipient in the study treatment.
      • Active uncontrolled bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
      • Any condition that, in the opinion of the Investigator or Sponsor, would interfere with the interpretation of study results.
    • Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Exclusion Criteria:
      • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
    • Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:
      • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
    • Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:
      • Received ≥ 1 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants who progressed during or within 6 months following the last dose of neoadjuvant, or perioperative therapy with curative intent.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
      • Known dihydropyrimidine dehydrogenase deficiency or thymidine synthase gene polymorphism predisposing the participant to 5-FU toxicity.
      • Known allergies to 5-FU or cisplatin.
    • Note: Other protocol-specified inclusion/exclusion criteria apply.` to `Key Inclusion Criteria:
      • At least 1 measurable lesion based on RECIST v1.1 as determined by the Investigator.
      • Resolved acute effects of any prior therapy to baseline severity or Grade 1 in accordance with National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) v5.0, except for adverse events (AEs) not constituting a safety risk per Investigator judgement.
    • Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma that is human epidermal growth factor receptor 2 (HER2) - negative and microsatellite stable (MSS)/proficient mismatch repair (pMMR).
      • Progressed during or after first line systemic therapy that includes a platinum and fluoropyrimidine doublet with or without anti-programmed death receptor 1 (PD-1)/programmed death ligand 1 (PD-L1)-directed therapy (that is, in the second line setting).
      • Consent to provide tumor tissue samples (baseline and on-treatment) is required for enrollment.
    • Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
      • Progressed during or after first line systemic therapy including a doublet of platinum and fluoropyrimidine or paclitaxel with or without anti-PD-1/PD-L1-directed therapy or anti-CTLA-4 and anti-PD-1/PD-L1-directed combination therapy.
      • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
      • Consent to provide archival tumor tissue sample (baseline) is required for enrolment.
    • Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Inclusion Criteria:
      • Histologically or cytologically documented unresectable, locally advanced or metastatic ESCC.
      • Consent to provide baseline tumor tissue is required.
      • Consent to provide results from prior PD-L1 IHC assay score by FDA-approved or equivalent PD-L1 IHC diagnostic tests.
      • Calculated creatinine clearance ≥60 mL/min.
    • Cohort D, Arms D1 and D2 (4L+ Colorectal Carcinoma [CRC]) - Specific Inclusion Criteria:
      • Histologically and/or cytologically documented unresectable advanced or metastatic colorectal adenocarcinoma. RAS, BRAF, and microsatellite instability/mismatch repair status for each participant must be documented, according to country level guidelines.
      • Participants who have no available therapies with a proven clinical benefit available in the participant's country per investigator. These therapies include the following: fluoropyrimidine, oxaliplatin, irinotecan-based chemotherapy, anti-VEGF biological therapy (eg, bevacizumab, aflibercept, ramucirumab), an anti-EGFR therapy (eg, cetuximab, panitumumab) if RAS wildtype unless right-sided, either trifluridine/tipiracil, fruqintinib or regorafenib, and a BRAF inhibitor (ie, encorafenib) in BRAF V600E mutant).
      • Participants who received oxaliplatin in the adjuvant setting and developed metastatic disease during or within 6 months of completing adjuvant therapy are considered eligible without receiving oxalipatin-based therapy in the metastatic setting.
      • Consent to provide baseline tumor tissue sample is required for enrolment.
    • Key Exclusion Criteria:
      • History of prior malignancy other than the cancer under study that is progressing or has required active treatment within the past 3 years.
      • Symptomatic or untreated central nervous system metastases, including leptomeningeal metastases, requiring concurrent treatment, including but not limited to surgery, radiation, and/or corticosteroids.
      • Major surgery requiring general anesthesia within 28 days prior to the first dose of study treatment, still recovering from prior surgery, or with surgery scheduled during the study.
      • Prior exposure to anti-C-C motif chemokine receptor 8 (CCR8) antibody.
      • History of Grade 4 allergic or anaphylactic reaction to any monoclonal antibody (mAb) therapy or any excipient in the study treatment.
      • Active uncontrolled bacterial, fungal, or viral infection including hepatitis B virus (HBV), hepatitis C virus (HCV), known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.
      • Any condition that, in the opinion of the Investigator or Sponsor, would interfere with the interpretation of study results.
    • Cohort A (2L Gastric, Gastro-esophageal-junction [GEJ], Esophageal Adenocarcinoma [EAC]) Specific Exclusion Criteria:
      • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
    • Cohort B (2L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:
      • Received ≥ 2 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
    • Cohort C (1L Esophageal Squamous Cell Carcinoma [ESCC]) - Specific Exclusion Criteria:
      • Received ≥ 1 prior systemic anticancer therapies for advanced or metastatic disease.
      • Participants who progressed during or within 6 months following the last dose of neoadjuvant, or perioperative therapy with curative intent.
      • Participants at high risk for developing esophageal fistula by clinical assessment or imaging, such as prior history or associated symptoms of esophageal fistula or T4 classification assessed by endoscopic ultrasound (EUS).
      • Known dihydropyrimidine dehydrogenase deficiency or thymidine synthase gene polymorphism predisposing the participant to 5-FU toxicity.
      • Known allergies to 5-FU or cisplatin.
    • Note: Other protocol-specified inclusion/exclusion criteria apply.`
  • 2026-03-03 00:59:11 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-19` to `2026-02-26`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-20` to `2026-03-02`
  • 2026-02-21 00:54:37 (Trial Update)
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-02-03` to `2026-02-19`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-02-05` to `2026-02-20`
    • Field `contactsLocationsModule.locations.[6]contacts.[0]phone` changed from `702-952-3406` to `702-487-9428`
  • 2026-02-10 07:03:39 (Trial Update)
    • Field `statusModule.statusVerifiedDate` changed from `2026-01` to `2026-02`
    • Field `statusModule.lastUpdateSubmitDate` changed from `2026-01-12` to `2026-02-03`
    • Field `statusModule.lastUpdatePostDateStruct.date` changed from `2026-01-13` to `2026-02-05`

📥 Download Full Data (CSV) 📥 Download Status Summary (CSV)

Monitoring Status

Trial ID Sponsor Update Status Conditions Phases Start End Enroll Last Updated
NCT04895709 Bristol-Myers Squibb Changed Recruiting Cervical Cancer, Gastric/Gastr… PHASE1, PHASE2 2021-05-27 2028-07-07 949 2026-02-23
NCT06479759 Shanghai Pulmonary Hospital, S… No Change Recruiting NSCLC, PD-1 PHASE2 2024-01-12 2025-12-12 50 2024-06-24
NCT05518045 LaNova Medicines Limited No Change Active Not Recruiting Advanced Solid Tumor PHASE1, PHASE2 2022-08-26 2026-03-31 392 2026-02-01
NCT06873854 LaNova Medicines Limited No Change Not Yet Recruiting Advanced Solid Tumor PHASE2 2025-03-26 2030-01-26 84 2025-03-10
NCT06825494 Chia Tai Tianqing Pharmaceutic… Changed Recruiting Advanced Solid Tumor PHASE1, PHASE2 2025-04-08 2026-09 194 2025-12-10
NCT06821503 Chia Tai Tianqing Pharmaceutic… Changed Recruiting Advanced Pancreatic Cancer PHASE1, PHASE2 2025-04-11 2028-12 72 2026-03-06
NCT05255484 LaNova Medicines Limited No Change Terminated Advanced Solid Tumor PHASE1, PHASE2 2022-05-26 2023-10-06 24 2023-10-24
NCT05199753 LaNova Australia Pty Limited No Change Completed Advanced Solid Tumor PHASE1, PHASE2 2022-03-16 2024-12-31 78 2025-09-06
NCT05859464 Zai Lab (Hong Kong), Ltd. No Change Terminated Malignant Solid Tumor PHASE1 2023-07-24 2025-08-28 34 2025-10-14
NCT05005403 AbbVie No Change Recruiting Non-Small Cell Lung Cancer, He… PHASE1 2021-11-01 2027-06 512 2025-10-27
NCT05581004 Genentech, Inc. No Change Recruiting Locally Advanced or Metastatic… PHASE1 2022-10-20 2027-02-28 450 2026-02-16
NCT06131398 Amgen No Change Active Not Recruiting Advanced Solid Tumors PHASE1 2024-03-07 2026-08-03 77 2025-12-19
NCT05690581 Beijing InnoCare Pharma Tech C… No Change Recruiting Advanced Solid Tumors and Hema… PHASE1 2023-02-23 2026-02-28 146 2024-12-22
NCT06304571 HC Biopharma Inc. No Change Recruiting Advanced Solid Tumor PHASE1 2024-02-27 2026-07-16 76 2025-04-30
NCT06963814 HC Biopharma Inc. No Change Recruiting Advanced Cancer PHASE1 2025-07-04 2027-05-30 252 2025-07-14
NCT06819735 Domain Therapeutics Australia … Changed Recruiting Advanced Solid Tumors PHASE1, PHASE2 2025-06-25 2028-01 125 2026-03-06
NCT07213882 Assistance Publique - Hôpitaux… No Change Not Yet Recruiting Cutaneous T Cell Lymphoma (CTC… EARLY_PHASE1 2026-01-01 2028-08-01 30 2025-10-02
NCT06911827 Qilu Pharmaceutical Co., Ltd. No Change Recruiting Advanced Solid Tumor PHASE1, PHASE2 2025-05-09 2028-12 90 2026-02-24
NCT05830045 Qilu Pharmaceutical Co., Ltd. No Change Recruiting Advanced Solid Tumors PHASE1 2023-05-19 2025-12-31 180 2024-06-25
NCT07011550 M.D. Anderson Cancer Center Changed Suspended Microsatellite-stable Colorect… PHASE2 2025-08-15 2030-07-01 7 2026-03-17
NCT05101070 Shionogi Changed Recruiting Solid Tumors PHASE1, PHASE2 2022-05-30 2028-05-31 282 2026-03-16
NCT07362186 LaNova Medicines Limited No Change Not Yet Recruiting Locally Advanced or Metastatic… PHASE3 2026-04-03 2028-09-28 400 2026-01-15
NCT06387628 Fudan University No Change Recruiting TNBC - Triple-Negative Breast … PHASE2 2024-07-10 2027-04-01 74 2024-08-01
NCT05537740 Bayer Changed Active Not Recruiting Advanced Solid Tumors PHASE1 2022-10-11 2027-05-04 129 2026-03-19
NCT05007782 Gilead Sciences No Change Recruiting Advanced Solid Tumor PHASE1 2021-08-18 2028-12 416 2025-12-26
NCT07205718 Takeda Changed Recruiting Advanced or Metastatic Solid T… PHASE1, PHASE2 2025-11-19 2029-12-21 223 2026-03-24
NCT05635643 Coherus Oncology, Inc. Changed Recruiting Advanced Solid Tumor, Head and… PHASE1 2022-12-15 2027-01-01 87 2026-03-17
NCT05935098 BeiGene Changed Terminated Advanced Solid Tumor, Metastat… PHASE1 2023-08-21 2026-01-27 99 2026-03-11
NCT06657144 Coherus Oncology, Inc. Changed Recruiting Metastatic Solid Tumor, Advanc… PHASE1 2025-04-01 2028-01 154 2026-03-27
NCT06620822 Shanghai Pulmonary Hospital, S… No Change Not Yet Recruiting Non Small Cell Lung Cancer PHASE2 2024-09-30 2027-09-30 296 2024-09-28
NCT07226856 Mayo Clinic No Change Recruiting Metastatic Pancreatic Adenocar… PHASE2 2025-12-12 2028-12-01 43 2025-12-19
NCT04810572 University of Sao Paulo Genera… No Change Completed Insulin Resistance, Inflammato… NA 2021-05-20 2022-12-19 162 2024-01-30
NCT02836067 Boston Medical Center No Change Completed HIV, Smoking NA 2017-06-15 2023-12-31 53 2024-01-03